ScholarIQanswers from OpenAlex & ORCID
Florian Lordick
ResearcherPublications, citations & collaboration network
Florian Lordick is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Florian Lordick have?
ScholarIQindexed works
Florian Lordick has 984 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Florian Lordick have?
ScholarIQcitation count
Florian Lordick has 49,587 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Florian Lordick?
ScholarIQh-index
Florian Lordick has an h-index of 92 in OpenAlex.
What is the i10-index of Florian Lordick?
ScholarIQi10-index
Florian Lordick has an i10-index of 379 in OpenAlex.
What is the ORCID of Florian Lordick?
ScholarIQorcid
The ORCID for Florian Lordick is on the source record.
What is the OpenAlex record for Florian Lordick?
ScholarIQopenalex
The OpenAlex for Florian Lordick is on the source record.
What are the most-cited papers on Florian Lordick?
ScholarIQmost cited works
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
Gunnar Folprecht, Thomas Gruenberger, Wolf O. Bechstein, Hans-Rudolf Raab, Florian Lordick, Jörg T. Hartmann, Hauke Lang, Andrea Frilling, Jan Stoehlmacher, Jürgen Weitz, Ralf Konopke, Christian Stroszczynski, Torsten Liersch, Detlev Ockert, Thomas Herrmann, Eray Goekkurt, Fabio Parisi, Claus‐Henning Köhne
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
Manish A. Shah, Takashi Kojima, Daniel Hochhauser, Peter C. Enzinger, Judith Raimbourg, Antoine Hollebecque, Florian Lordick, Sung‐Bae Kim, Masahiro Tajika, Heung Tae Kim, A. Craig Lockhart, Hendrik-Tobias Arkenau, Farid El-Hajbi, Mukul Gupta, Per Pfeiffer, Qi Liu, Jared Lunceford, Soonmo Peter Kang, Pooja Bhagia, Ken Kato
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung‐Bae Kim, Jaffer A. Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Longzhen Zhang, Tienan Yi, Jong‐Mu Sun, Jianhua Chen, Guohua Yu, Chen‐Yuan Lin, Hiroki Hara, Qing Bi, Taroh Satoh, Roberto Pazo-Cid, Hendrick-Tobias Arkenau, Christophe Borg, Florian Lordick, Liyun Li, Ningning Ding, Aiyang Tao, Jingwen Shi, Eric Van Cutsem, for the RATIONALE-302 Investigators
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG
Trevor Leong, B. Mark Smithers, Karin Haustermans, Michael Michael, Val Gebski, Danielle Miller, John Zalcberg, Alex Boussioutas, Michael Findlay, Rachel O’Connell, Jaclyn Verghis, David J. Willis, Tomas Kron, Melissa Crain, William K. Murray, Florian Lordick, Carol J. Swallow, Gail Darling, John Simes, Rebecca Wong